tiprankstipranks
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
US Market
CAMP
CAMP4 Therapeutics Corporation
RESEARCH TOOLSreports
Want to see CAMP full AI Analyst Report?

CAMP4 Therapeutics Corporation (CAMP) Stock Forecast & Price Target

128 Followers
See the Price Targets and Ratings of:

CAMP Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
CAMP4
Therapeutics Corporation
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAMP Stock 12 Month Forecast

Average Price Target

$8.36
▲(86.13% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for CAMP4 Therapeutics Corporation in the last 3 months. The average price target is $8.36 with a high forecast of $12.00 and a low forecast of $6.50. The average price target represents a 86.13% change from the last price of $4.49.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.357142857142858,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.6523076923076925,5.264615384615385,5.876923076923077,6.489230769230769,7.101538461538462,7.713846153846154,8.326153846153847,8.938461538461539,9.55076923076923,10.163076923076924,10.775384615384617,11.387692307692308,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.372087912087912,4.704175824175824,5.036263736263736,5.3683516483516485,5.700439560439561,6.032527472527473,6.364615384615385,6.696703296703297,7.028791208791209,7.360879120879121,7.692967032967033,8.025054945054945,{"y":8.357142857142858,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.229230769230769,4.418461538461538,4.607692307692307,4.796923076923077,4.986153846153846,5.1753846153846155,5.364615384615385,5.553846153846154,5.743076923076924,5.932307692307692,6.121538461538462,6.310769230769231,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$8.36Lowest Price Target$6.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CAMP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/25/26
Analysts' Top Healthcare Picks: TriSalus Life Sciences (TLSI), CAMP4 Therapeutics Corporation (CAMP)
J.P. Morgan Analyst forecast on CAMP
Anupam Rama
J.P. Morgan
J.P. Morgan
$9
Buy
100.45%
Upside
Upgraded
06/22/26
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan
Chardan Capital Analyst forecast on CAMP
Keay Nakae
Chardan Capital
Chardan Capital
$6.5
Buy
44.77%
Upside
Initiated
06/10/26
CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital
Piper Sandler Analyst forecast on CAMP
Edward Tenthoff
Piper Sandler
Piper Sandler
$12
Buy
167.26%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC), CAMP4 Therapeutics Corporation (NASDAQ: CAMP) and Aquestive Therapeutics (NASDAQ: AQST)
Cantor Fitzgerald Analyst forecast on CAMP
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$7
Buy
55.90%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), MoonLake Immunotherapeutics (NASDAQ: MLTX) and CAMP4 Therapeutics Corporation (NASDAQ: CAMP)
Wedbush Analyst forecast on CAMP
Yun Zhong
Wedbush
Wedbush
$8
Buy
78.17%
Upside
Reiterated
05/08/26
Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028
Rodman & Renshaw Analyst forecast on CAMP
Seema Sheoran
Rodman & Renshaw
Rodman & Renshaw
$7
Buy
55.90%
Upside
Initiated
04/14/26
Camp4 Therapeutics initiated with a Buy at Rodman & RenshawCamp4 Therapeutics initiated with a Buy at Rodman & Renshaw
Leerink Partners Analyst forecast on CAMP
Mani Foroohar
Leerink Partners
Leerink Partners
$8→$9
Buy
100.45%
Upside
Reiterated
04/02/26
Camp4 Therapeutics price target raised to $9 from $8 at LeerinkCamp4 Therapeutics price target raised to $9 from $8 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CAMP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/25/26
Analysts' Top Healthcare Picks: TriSalus Life Sciences (TLSI), CAMP4 Therapeutics Corporation (CAMP)
J.P. Morgan Analyst forecast on CAMP
Anupam Rama
J.P. Morgan
J.P. Morgan
$9
Buy
100.45%
Upside
Upgraded
06/22/26
Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan
Chardan Capital Analyst forecast on CAMP
Keay Nakae
Chardan Capital
Chardan Capital
$6.5
Buy
44.77%
Upside
Initiated
06/10/26
CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital
Piper Sandler Analyst forecast on CAMP
Edward Tenthoff
Piper Sandler
Piper Sandler
$12
Buy
167.26%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC), CAMP4 Therapeutics Corporation (NASDAQ: CAMP) and Aquestive Therapeutics (NASDAQ: AQST)
Cantor Fitzgerald Analyst forecast on CAMP
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$7
Buy
55.90%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), MoonLake Immunotherapeutics (NASDAQ: MLTX) and CAMP4 Therapeutics Corporation (NASDAQ: CAMP)
Wedbush Analyst forecast on CAMP
Yun Zhong
Wedbush
Wedbush
$8
Buy
78.17%
Upside
Reiterated
05/08/26
Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028
Rodman & Renshaw Analyst forecast on CAMP
Seema Sheoran
Rodman & Renshaw
Rodman & Renshaw
$7
Buy
55.90%
Upside
Initiated
04/14/26
Camp4 Therapeutics initiated with a Buy at Rodman & RenshawCamp4 Therapeutics initiated with a Buy at Rodman & Renshaw
Leerink Partners Analyst forecast on CAMP
Mani Foroohar
Leerink Partners
Leerink Partners
$8→$9
Buy
100.45%
Upside
Reiterated
04/02/26
Camp4 Therapeutics price target raised to $9 from $8 at LeerinkCamp4 Therapeutics price target raised to $9 from $8 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CAMP4 Therapeutics Corporation

3 Months
Steven SeedhouseCantor Fitzgerald
Success Rate
3/6 ratings generated profit
50%
Average Return
+13.32%
Copying Steven Seedhouse's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +13.32% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
3/6 ratings generated profit
50%
Average Return
+16.48%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.48% per trade.
2 Years
Yun ZhongWedbush
Success Rate
3/7 ratings generated profit
43%
Average Return
+31.11%
Copying Yun Zhong's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +31.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAMP Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
5
7
9
8
Buy
3
2
2
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
7
9
12
11
In the current month, CAMP has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CAMP average Analyst price target in the past 3 months is 8.36.
Each month's total comprises the sum of three months' worth of ratings.

CAMP Financial Forecast

CAMP Earnings Forecast

Next quarter’s earnings estimate for CAMP is -$0.21 with a range of -$0.27 to -$0.13. The previous quarter’s EPS was -$0.32. CAMP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CAMP has Performed in-line its overall industry.
Next quarter’s earnings estimate for CAMP is -$0.21 with a range of -$0.27 to -$0.13. The previous quarter’s EPS was -$0.32. CAMP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CAMP has Performed in-line its overall industry.

CAMP Sales Forecast

Next quarter’s sales forecast for CAMP is $1.62M with a range of $0.00 to $2.80M. The previous quarter’s sales results were $1.29M. CAMP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CAMP has Performed in-line its overall industry.
Next quarter’s sales forecast for CAMP is $1.62M with a range of $0.00 to $2.80M. The previous quarter’s sales results were $1.29M. CAMP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CAMP has Performed in-line its overall industry.

CAMP Stock Forecast FAQ

What is CAMP’s average 12-month price target, according to analysts?
Based on analyst ratings, CAMP4 Therapeutics Corporation’s 12-month average price target is 8.36.
    What is CAMP’s upside potential, based on the analysts’ average price target?
    CAMP4 Therapeutics Corporation has 86.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CAMP a Buy, Sell or Hold?
          CAMP4 Therapeutics Corporation has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is CAMP4 Therapeutics Corporation’s price target?
            The average price target for CAMP4 Therapeutics Corporation is 8.36. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $6.50. The average price target represents 86.13% Increase from the current price of $4.49.
              What do analysts say about CAMP4 Therapeutics Corporation?
              CAMP4 Therapeutics Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of CAMP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.